Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%. Since GVHD contributes to morbidity and mortality after MUD-BMT, a more effective prophylactic regimen is needed in order to prevent these transplant-associated complications. Recently, we described that mycophenolate mofetil (MMF, CellCept), an immunosuppressive agent successfully used for the prevention of acute rejection in renal allograft recipients, can safely and effectively be used for the treatment of aGVHD in hematopoietic stem cell transplantation. Information on the i.v. 2, S16-S19.
In the pathogenesis of graft-versus-host disease (GVHD) donor lymphocytes recognize HLA class I or II differences in the host. Once activated Th0 lymphocytes differentiate into Th1 and Th2 cells and synthesize and are secreting with activated CD8 + lymphocytes cytokines like interferon ␥ (IFN ␥), interleukin -2, -3, -4, -5, -9, -10, -13, and granulocyte-macrophage colony-stimulating factor (GM-CSF). [1] [2] [3] [4] These cytokines stimulate NK cells as well as monocytes/macrophages to produce either additional cytokines like TNF-␣ and IL-12, or attack target cells. IL-12, for example, appears to be the key stimulatory cytokine for TH1 cells leading to further lymphocyte/macrophage activation, leukocyte infiltration, and cytotoxic T cell generation, whereas the TH2 cell-mediated immunoreactions due to IgE and eosinophilic granulocytes are inhibited. In addition, the literature indicates that dendritic cells as Correspondence: MG Kiehl, Dept of Hematology/Oncology, BMT Unit, Dr Ottmar-Kohler-Str. 2, 55743 Idar-Oberstein, Germany highly professional antigen presenting cells are also involved in the pathogenesis of GVHD. Effective techniques for GVHD prevention involve depletion of donor T lymphocytes from the donor marrow inocculum, most often coupling immunologic recognition with depletion techniques by immunomagnetic beads, complement cytotoxicity, or toxin immunoconjugates. Although vigorous T lymphocyte depletion prevents acute GVHD, it might also increase the risk of graft failure and the relapse rate after transplantation, due to the absence of the graft-versus-leukemia effect. 5 Pharmacological immunosuppression administered over several months after transplantation can prevent or blunt the initiating T cell recognition and proliferative response triggering GVHD allowing the development of immune tolerance and complete lymphohematopoietic chimerism. Methotrexate (15 mg/kg +1, 10 mg/kg BW +3, +6, (+11)), corticosteroids, ATG, and cyclosporine are used for prophylaxis of GVHD, reducing both the frequency and severity of GVHD. 6, 7 The most widely excepted pharmacologic immunosuppressive regimens for GVHD prophylaxis are listed in Table 1 .
Despite these advantages in immunosuppression and GVHD prophylaxis, severe GVHD grade II-IV is still one of the major concerns in stem cell transplantation occurring in approximately 50% of transplanted patients. [8] [9] [10] [11] [12] [13] [14] Therefore, new regimens are needed in order to provide effective GVHD prophylaxis without hampering graft-versus-leukemia activity.
Recently, it has been shown that the oral formulation of mycophenolate mofetil (MMF, CellCept, Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany), an immunosuppressant successfully used for prevention of acute rejection in renal allograft recipients, [15] [16] [17] can safely and effectively be used for the treatment of aGVHD. 18, 19 As the i.v. formulation of MMF is now available we started a trial using MMF in combination with cyclosporine and prednisolone Table 1 Established pharmacologic immunosuppressive regimens for the prevention of GVHD in stem cell transplant recipients 7, 8, 11, [25] [26] [27] 
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in the prophylaxis of acute GVHD in stem cell transplant recipients.
Patients and methods
After approval by the ethics committee seven patients hematopoietic stem cell transplanted for hematologic malignancy were prospectively studied. The conditioning regimen included total body irradiation (TBI) and cyclophosphamide (CY) in three patients, and busulfan (BU) and cyclophosphamide in four patients. The TBI/CY regimen consisted of TBI with a total dose of 13.5 Gy on days −6, −5 and −4, CY 60 mg/kg BW once daily intravenously on days −3 and −2 followed by transplantation on day 0. The BU/CY regimen consisted of busulfan administered in a dose of 16 mg/kg orally, daily, over 4 days (−7 to −3), followed by cyclophosphamide 60 mg/kg BW on days −3 and −2.
Engraftment was defined as the first of 2 successive days after marrow transplantation with a neutrophil count Ͼ0.5 × 10 9 /l. Acute GVHD prophylaxis for HLA mismatched related BMT as well as for matched or mismatched unrelated transplants consists of a combination of CsA (initial dose: 5 mg/kg) daily, starting on day −3 and i.v. MMF 1 g two times per day starting on day 0 until day 21. From day 22 until day 60 patients receive MMF p.o. at the same dosage. Starting on day +7 all patients received prednisolone at a dose of 0.5 mg/kg daily and from day +14 until day +28 1 mg/kg daily, than tapered. Acute GVHD was graded and staged according to the Consensus Conference on aGVHD grading and patients were clinically re-evaluated daily. 19 Blood samples for pharmacokinetic analysis were obtained on day 5 and day 20 during i.v. MMF application, and on day 30 of p.o. MMF treatment. All blood samples were collected in tubes containing EDTA as anticoagulant. In order to determine total MPA and MPAG concentrations, plasma was separated and stored at −20°C until analysis.
Plasma concentrations of MPA and MPAG were determined by reversed phase high-performance liquid chromatography (HPLC), as described elsewhere.
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Results
Patients' characteristics are depicted in Table 2 . All patients received peripheral blood from unrelated donors. Seven M = male; F = female; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; PB = peripheral blood stem cells.
Bone Marrow Transplantation patients, treated so far, engrafted with a leukocyte cell count of у1000/l on day 12 (10-22) (median, (range)). Platelets remained stable above 50 000/l after a median of 15 days. Acute GVHD grade II-IV was observed in three patients (two patients cutaneous GVHD grade II, one patient acute GVHD of the bowel grade IV). Two of these patients died; patient 3 due to refractory GVHD of the bowel and patient 6 of respiratory failure due to severe rapid progressive pneumonia despite mechanical ventilation and broad antibiotic and antimycotic treatment. Mycophenolic acid (MPA) plasma levels on day 5 of treatment are shown in Figure 1 . Levels on day 20 during i.v. treatment were similar. Plasma levels are high immediately after MMF infusion but decrease rapidly within 2 hours after infusion. We did not observe a difference in MPA plasma levels comparing patients with and without GVHD as well as MMF-associated side-effects, in particular with regard to the intestinal tract.
Discussion
Despite the prophylactic use of cyclosporine alone or in combination with methotrexate and/or prednisolone, GVHD still develops in a high percentage of patients and severe GVHD remains the major risk of transplant-related morbidity and mortality. 22 Therefore, new immunosuppressive drugs are needed in order to prevent GVHD, if possible, without affecting graft-versus-leukemia effects. Ours as well as first clinical data from other groups on the oral formulation of MMF are promising regarding the prophylaxis and treatment of aGVHD. 23, 24 As many patients suffer from severe mucositis enabling oral drug uptake after conditioning chemo-or radio-chemotherapy the i.v. formulation of MMF might be the useful alternative for aGVHD prophylaxis. We are presenting our first experience with i.v. MMF in patients matched unrelated stem cell transplanted for hematologic malignancies.
In adult renal transplant recipients receiving 2 g MMF/day p.o. in combination with CsA and prednisolone, a median pre-dose MPA concentration of 0.73 was found 1 week after transplantation. 20 The present investigation demonstrates that the median pre-dose trough concentration of 0.1 mg/l observed in patients receiving the i.v. drug was clearly lower when compared to renal transplant recipients. MPA plasma levels decrease rapidly after the end of infusion reaching pre-dose levels after a median time interval of 120 min. Comparing our patients with and without aGVHD we did not observe any differences with regard to MPA plasma levels. It is of note that all patients developing aGVHD were HLA identical whereas two of the patients without aGVHD showed HLA disparities. This raises the question of whether the dosage of 2 × 1 g/day is sufficient in GVHD prophylaxis. Since no data on i.v. MMF or p.o. MMF and plasma MPA levels in stem cell transplant patients are available demonstrating a clear dose-response, we recently started a multicenter randomized trial comparing 1 g/twice a day vs 1.5 g/twice a day in combination with cyclosporine A and prednisone with a control group receiving CsA, MTX and prednisone for GVHD prophylaxis.
Diarrhea is the most frequent side-effect observed during MMF treatment. In our patients without gut involvement of GVHD we did not observe an increased frequency of diarrhea using the MMF dose of two times 1 g/day.
In conclusion, MMF seems to be effective in the prophylaxis of acute GVHD after hematopoietic stem cell transplantation. Whether 2 g daily is the appropriate dose remains to be determined. The relevance of plasma MPA levels with regard to the MMF dosing is not clear yet and needs further evaluation. Low concentrations of MPA might suggest inadequate levels of the active metabolite in these patients. Therefore, a higher dose of MMF in these patients might be necessary.
